Current Report Filing (8-k)
October 28 2020 - 4:16PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date
of Report (Date of earliest event reported): October 28, 2020
ACTINIUM
PHARMACEUTICALS, INC.
(Exact
name of registrant as specified in its charter)
Delaware
|
|
001-36374
|
|
74-2963609
|
(State or other
jurisdiction
of incorporation)
|
|
(Commission File
Number)
|
|
(IRS Employer
Identification No.)
|
275
Madison Avenue, 7th Floor, New York, NY 10016
(Address
of Principal Executive Offices)
Registrant’s
telephone number: (646) 677-3870
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2. below):
|
☐
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
☐
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
|
|
Trading
Symbol(s)
|
|
Name
of each exchange on which registered
|
Common Stock,
par value $0.001 per share
|
|
ATNM
|
|
NYSE American
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
7.01 Regulation FD Disclosure.
On
October 28, 2020 , Actinium Pharmaceuticals, Inc. (the “Company”) issued a letter to shareholders, which is attached
hereto as Exhibit 99.1. The Company undertakes no obligation to update, supplement or amend the materials attached hereto as Exhibit
99.1.
In
accordance with General Instruction B.2 of Form 8-K, the information in this Item 7.01 of this Current Report on Form 8-K, including
Exhibit 99.1, shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as
amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated
by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, except as shall be expressly set
forth by reference in such a filing. Furthermore, the furnishing of information under Item 7.01 of this Current Report on Form
8-K is not intended to constitute a determination by the Company that the information contained herein, including the exhibits
hereto, is material or that the dissemination of such information is required by Regulation FD.
Item
9.01 Financial Statements and Exhibits.
(d)
Exhibits
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
Actinium Pharmaceuticals,
Inc.
|
|
|
Date: October 28, 2020
|
/s/
Sandesh Seth
|
|
Name: Sandesh Seth
|
|
Title: Chairman and Chief Executive Officer
|
2
Actinium Pharmaceuticals (AMEX:ATNM)
Historical Stock Chart
From Aug 2024 to Sep 2024
Actinium Pharmaceuticals (AMEX:ATNM)
Historical Stock Chart
From Sep 2023 to Sep 2024